Novira Therapeutics, a US-based drug discovery company, has raised $23m in its series A round from a consortium including China-based WuXi PharmaTech.
Venture capital firms 5AM Ventures and Canaan Partners co-led the A round, and were joined by peers BioAdvance, Mid-Atlantic Angel Group, Robin Hood Ventures and Delaware Crossing Investment Group.
Osvaldo (Lalo) Flores, the co-founder, president and chief scientific officer of Novira, formerly known as Molecmo Nanobiotechnologies, was previously director of antiviral research at US-listed drugs group Merck.